1
|
Slavetinsky J, Lehmann E, Slavetinsky C, Gritsch L, van Dalen R, Kretschmer D, Bleul L, Wolz C, Weidenmaier C, Peschel A. Wall Teichoic Acid Mediates Staphylococcus aureus Binding to Endothelial Cells via the Scavenger Receptor LOX-1. ACS Infect Dis 2023; 9:2133-2140. [PMID: 37910786 DOI: 10.1021/acsinfecdis.3c00252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2023]
Abstract
The success of Staphylococcus aureus as a major cause for endovascular infections depends on effective interactions with blood-vessel walls. We have previously shown that S. aureus uses its wall teichoic acid (WTA), a surface glycopolymer, to attach to endothelial cells. However, the endothelial WTA receptor remained unknown. We show here that the endothelial oxidized low-density lipoprotein receptor 1 (LOX-1) interacts with S. aureus WTA and permits effective binding of S. aureus to human endothelial cells. Purified LOX-1 bound to isolated S. aureus WTA. Ectopic LOX-1 expression led to increased binding of S. aureus wild type but not of a WTA-deficient mutant to a cell line, and LOX-1 blockage prevented S. aureus binding to endothelial cells. Moreover, WTA and LOX-1 expression levels correlated with the efficacy of the S. aureus-endothelial interaction. Thus, LOX-1 is an endothelial ligand for S. aureus, whose blockage may help to prevent or treat severe endovascular infections.
Collapse
Affiliation(s)
- Jessica Slavetinsky
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
| | - Esther Lehmann
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
| | - Christoph Slavetinsky
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
- Pediatric Surgery and Urology, University Children's Hospital Tübingen, Tübingen 72076, Germany
| | - Lisa Gritsch
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
| | - Rob van Dalen
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
| | - Dorothee Kretschmer
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
| | - Lisa Bleul
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
| | - Christiane Wolz
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
| | - Christopher Weidenmaier
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
| | - Andreas Peschel
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen72076, Germany
- Cluster of Excellence EXC 2124 "Controlling Microbes to Fight Infections", University of Tübingen, Tübingen 72076, Germany
- German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen 72076 , Germany
| |
Collapse
|
2
|
Slavetinsky CJ, Hauser JN, Gekeler C, Slavetinsky J, Geyer A, Kraus A, Heilingbrunner D, Wagner S, Tesar M, Krismer B, Kuhn S, Ernst CM, Peschel A. Sensitizing Staphylococcus aureus to antibacterial agents by decoding and blocking the lipid flippase MprF. eLife 2022; 11:66376. [PMID: 35044295 PMCID: PMC8806190 DOI: 10.7554/elife.66376] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 01/18/2022] [Indexed: 11/13/2022] Open
Abstract
The pandemic of antibiotic resistance represents a major human health threat demanding new antimicrobial strategies. MprF is the synthase and flippase of the phospholipid lysyl-phosphatidylglycerol that increases virulence and resistance of methicillin-resistant Staphylococcus aureus (MRSA) and other pathogens to cationic host defense peptides and antibiotics. With the aim to design MprF inhibitors that could sensitize MRSA to antimicrobial agents and support the clearance of staphylococcal infections with minimal selection pressure, we developed MprF-targeting monoclonal antibodies, which bound and blocked the MprF flippase subunit. Antibody M-C7.1 targeted a specific loop in the flippase domain that proved to be exposed at both sides of the bacterial membrane, thereby enhancing the mechanistic understanding of bacterial lipid translocation. M-C7.1 rendered MRSA susceptible to host antimicrobial peptides and antibiotics such as daptomycin, and it impaired MRSA survival in human phagocytes. Thus, MprF inhibitors are recommended for new anti-virulence approaches against MRSA and other bacterial pathogens.
Collapse
Affiliation(s)
| | | | - Cordula Gekeler
- Department of Infection Biology, Eberhard Karls University Tübingen
| | | | - André Geyer
- Department of Infection Biology, Eberhard Karls University Tübingen
| | | | | | - Samuel Wagner
- Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen
| | | | - Bernhard Krismer
- Department of Infection Biology, Eberhard Karls University Tübingen
| | - Sebastian Kuhn
- Department of Infection Biology, Eberhard Karls University Tübingen
| | - Christoph M Ernst
- Department of Molecular Biology and Center for Computational and Integrative Biology, Broad Institute
| | - Andreas Peschel
- Department of Infection Biology, Eberhard Karls University Tübingen
| |
Collapse
|